Latest Biotech News

MeiraGTx secured up to $400 million from Oberland Capital to fund late-stage gene therapy programs for rare eye and mouth conditions, positioning the company for potential commercialization...

Vertex announced it will acquire Crinetics Pharmaceuticals in a $10 billion deal, the largest in Vertex’s history, as the cystic fibrosis leader extends beyond its anchor franchise into...

Novartis agreed to acquire Myricx Bio for up to $1.5 billion to add a next-generation antibody-drug conjugate (ADC) payload platform built around N-myristoyltransferase inhibitor (NMTi) warheads....

The U.S. FDA approved Vera Therapeutics’ Trutakna (atacicept) for immunoglobulin A nephropathy (IgAN), making it the first dual BAFF/APRIL inhibitor cleared for the condition. The accelerated...

Prime Medicine said it won an arbitration dispute against Beam Therapeutics over gene-editing technology restrictions in a 2019 agreement. An arbitrator ruled Prime’s work on a treatment for...

Breakthrough Genomics is preparing to launch an updated version of its AI-driven Virtual Geneticist genome analysis platform toward the end of summer, with a new agentic AI capability aimed at...

Oberland Capital is also backing MeiraGTx with structured payments to help bring two late-stage gene therapies to commercialization, extending the funding runway at a time when approvals for...

Satellos Bioscience provided early evidence that its oral Duchenne muscular dystrophy candidate is biologically active in adult patients ahead of a key readout in children later this year. The...

Biocartis and Discovery Life Sciences announced a strategic collaboration aimed at accelerating precision oncology companion diagnostic execution using Biocartis’ Idylla PCR-based platform. The...

Bifrost Biosystems signed a commercial supply agreement with Illumina to integrate Illumina sequencing-by-synthesis (SBS) chemistry into Bifrost’s optical pooled screening (OPS) platform. The...

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in a $10 billion cash deal, the largest M&A transaction in Vertex’s history, to broaden beyond cystic fibrosis into...

The FDA approved Vera Therapeutics’ Trutakna (atacicept) for IgA nephropathy (IgAN), giving the biotech an accelerated approval for adults with primary IgAN at risk for disease progression. The...

Novartis agreed to acquire Myricx Bio in a deal valued at up to $1.5 billion to strengthen its oncology pipeline with a next-generation antibody-drug conjugate payload platform. The London-based...

Bristol Myers Squibb disclosed that its confirmatory phase 3 Krystal-10 trial of Krazati (adagrasib) plus Erbitux (cetuximab) failed to meet primary endpoints in previously treated KRAS...

BIOCENTURY reports that FDA cleared Saol to resubmit its ultra-rare disease NDA, reducing the need for a new trial. The update is framed as another reversal in the so-called “Makary era” approach...

Oberland Capital agreed to fund MeiraGTx with up to $400 million, according to the reported financing deal. The transaction is positioned as a vote of confidence in MeiraGTx’s late-stage gene...

A University at Buffalo-led team reported in Communications Medicine that AI can identify previously invisible cortical lesions in multiple sclerosis by reprocessing existing MRI datasets. The...

Biocartis and Discovery Life Sciences announced a strategic collaboration to deliver precision oncology solutions using Biocartis’ Idylla PCR-based platform and Discovery’s clinical laboratory...

EG427, a gene therapy specialist focused on chronic neuro-urology indications, closed a €33 million (US$37.7 million) Series C after changing its brand identity, according to the report. The...

Thermo Fisher received FBI National DNA Index System approval for its Applied Biosystems RapidIntel Plus cartridge for rapid DNA profiling in qualifying forensic samples. With the FBI approval,...